HIGHLIGHTS
- who: Gregory D. Huhn from the 0612, USA have published the research: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study, in the Journal: (JOURNAL) of 21/Oct/2014
- what: The aim of this analysis was to evaluate EMERALD outcomes across subgroups of patients based on demo‑ graphic characteristics prior treatment experience and baseline antiretroviral regimen. ing). The overall findings from this analysis show that switching to D/C/F/TAF may be an option for a broad range of virologically suppressed . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.